Brief: Compugen Reports Q2 Loss Per Share $0.08
July 30 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN REPORTS SECOND QUARTER 2020 RESULTS
* Q2 LOSS PER SHARE $0.08
* ENROLLMENT IN COM701 PHASE 1 MONOTHERAPY BIOMARKER-DRIVEN
EXPANSION COHORT ON-TRACK
* INITIATION OF TRIPLE COMBINATION STUDY ACCELERATING
EVALUATION
OF DNAM AXIS HYPOTHESIS ON-TRACK FOR 2H 2020
Source text for Eikon: ID:nPn3JjJR9a
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025